2019-02-14 08:30:00
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
RARE: Ultragenyx Pharmaceutical Inc.
2019-01-04 08:30:00
Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
RARE has been consolidating into a textbook falling wedge pattern and is trading just on the underside of the volume point of control. RSI is displaying a bullish divergence and I like this to make a move back near $70 in the next 2-3 months.
